Patents Assigned to CAERUS THERAPEUTICS, INC.
  • Publication number: 20230138520
    Abstract: The disclosure provides for humanized antibodies, and fragments thereof, that are capable of binding to and killing human myeloma and ovarian cancer cells. The antibodies and their fragments are useful for therapeutic, diagnostic, and research purposes.
    Type: Application
    Filed: January 14, 2021
    Publication date: May 4, 2023
    Applicant: CAERUS THERAPEUTICS, INC.
    Inventor: Cohava GELBER
  • Patent number: 11623953
    Abstract: Provided herein are antibodies and related polypeptides that bind specifically to CEACAM6. The antibodies and/or polypeptides can be configured as bispecific T cell engagers. The antibodies and/or polypeptides can also be configured as chimeric antigen receptors. Also provided are methods of detection and treatment of cancer, for example, pancreatic cancer, using the antibodies and related polypeptides herein.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: April 11, 2023
    Assignees: Caerus Therapeutics, Inc., University of Georgia Research Foundation, Inc.
    Inventors: J. Michael Pierce, Cohava Gelber
  • Publication number: 20210371516
    Abstract: Provided herein are antibodies and related polypeptides that bind specifically to CEACAM6. The antibodies and/or polypeptides can be configured as bispecific T cell engagers. The antibodies and/or polypeptides can also be configured as chimeric antigen receptors. Also provided are methods of detection and treatment of cancer, for example, pancreatic cancer, using the antibodies and related polypeptides herein.
    Type: Application
    Filed: February 27, 2018
    Publication date: December 2, 2021
    Applicants: CAERUS THERAPEUTICS, INC., UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
    Inventors: J. Michael PIERCE, Cohava GELBER